Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Scientific Screening Library Advances Drug Discovery Research at Temple University’s Moulder Center

Published: Thursday, October 20, 2011
Last Updated: Wednesday, October 19, 2011
Bookmark and Share
20,000-molecule Maybridge collection will help identify compound candidates to treat a wide range of diseases.

Thermo Fisher Scientific Inc. has announced that the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy has selected the company’s Maybridge screening libraries to identify compounds that might be useful in treating health problems as diverse as Alzheimer’s disease, cancer and drug dependency.

Thermo Fisher will provide the Moulder Center with a custom compound library based initially on the 14,000-strong HitFinder™ collection. This library will be used within the university as well as by its continually expanding list of academic, pharmaceutical and biotechnology partners.

The Moulder Center is led by Dr. Magid Abou-Gharbia, a highly respected scientist whose work in the drug discovery field has produced five FDA-approved therapeutics. The center conducts in-house research using its laboratory facilities.

These studies are currently focused on the identification of compounds targeting drug addiction and withdrawal symptoms as well as the development of Alzheimer’s disease.

Each is built on a foundation of rational design that is based on “Lipinski's Rule of Five,” which utilizes both computer aided analysis and high-throughput screening assays.

With an expanded Maybridge HitFinder library of more than 20,000 candidate molecules, the team at the Moulder Center hopes to screen a wide range of compounds.

“We needed a large but manageable library that was still flexible enough to meet the needs of our drug discovery programs and those of our collaborators,” said Dr. Abou-Gharbia.

Dr. Abou-Gharbia continued, “We aim to expand the already excellent HitFinder library by taking advantage of the extensive range of related compounds offered by the Maybridge service. The Maybridge experts provided exceptional technical and data support, making it easy to add the new molecules to our collection database.”

In addition to conducting its own research, the Moulder Center collaborates with many research partners, using its expertise and resources to enrich and expand their drug discovery pipelines.

“One of our primary aims is to provide a conduit that helps researchers move forward from their exciting early stage research and turn their discoveries into drugs to treat disease,” said Dr. Abou-Gharbia.

Dr. Abou-Gharbia continued, “Plugging this gap will help to ensure that research laboratories, especially those in the academic sector, have the support they need to move efficiently and accurately through the drug discovery process.”

The Maybridge HitFinder collection is a premier offering of drug-like screening compounds that uses an industry standard clustering algorithm to select a statistically representative sample of the full collection.

All compounds have purity greater than 90 percent and have been selected to be non-reactive, ensuring fewer false positives and higher-quality results.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Scientific to Acquire Life Technologies Corporation
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.
Monday, April 15, 2013
Thermo Fisher Scientific and bioMérieux Renew Partnership
The companies have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin testing.
Wednesday, October 03, 2012
Thermo Fisher Scientific Opens New Biomarker Translational Center
Goal is to accelerate MS-based biomarker discovery and its translation into development of routine clinical assays.
Wednesday, September 07, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!